Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19Case Reports Published on 2020-11-152023-07-12 Journal: Internal medicine (Tokyo, Japan) [Category] SARS, [키워드] acute hypertriglyceridaemia COVID-19 Tocilizumab [DOI] 10.2169/internalmedicine.5244-20 PMC 바로가기 [Article Type] Case Reports
Tocilizumab‐induced cytomegalovirus colitis in a patient with COVID‐19Case Report Published on 2020-11-122024-09-02 Journal: Clinical Case Reports [Category] 대상포진, [키워드] COVID‐19 Cytomegalovirus colitis double‐barrel colostomy Lower gastrointestinal bleeding Tocilizumab [DOI] 10.1002/ccr3.3487 PMC 바로가기 [Article Type] Case Report
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysisMeta-Analysis Published on 2020-11-052022-10-04 Journal: Clinical microbiology and infection : the official [Category] MERS, SARS, 임상, 진단, [키워드] 95%CI adjusted adjusted RR adverse event approach association certainty of evidence citation Cohort cohort study cohorts concerning Controlled COVID-19 COVID-19 patients COVID-19 severity Daily death did not reduce Efficacy elevated eligibility criteria eligible evaluate evaluated Evidence examined FIVE Google higher risk hospitalized COVID-19 patients IL-6 IL-6 receptor Infection interleukin-6 lower mortality mechanical ventilation Meta-analysis moderate Mortality Multiorgan objective observational study observé Other OVID participant Patient patients Placebo Randomized controlled trial RCT RCTs reduce Result risk risk of bia Risk of bias risk ratio RRs severe coronavirus disease Standard of care syndrome systematic review Tocilizumab Toxicity treat Treatment Web of Science while [DOI] 10.1016/j.cmi.2020.10.036 PMC 바로가기 [Article Type] Meta-Analysis
Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case seriesCase Series Published on 2020-11-052022-10-04 Journal: Annals of Medicine and Surgery [Category] 치료법, [키워드] Acute respiratory failure Administered administration Admission adverse effect analyzed Antibiotics antibody anticoagulation antivirals ARF Bacterial infection case sery characterized chronic Comorbidity COVID-19 COVID-19 patients COVID-19 pneumonia Critical Critically ill critically ill patients develop Dexamethasone dosage examined had more hallmark hospital hyperinflammation ICU infections intensive care interleukin-6 receptor intravenous intravenous infusion male measure mechanical ventilation mechanically ventilated mechanically ventilated patient monoclonal Mortality nine nosocomial not affect not significant outcome overall mortality oxygen support Oxygen therapy Patient Physiology Pneumonia Prevalence Prophylactic receiving Respiratory failure retrospective Safe survival rate therapy Tocilizumab tocilizumab therapy Treatment ventilated patient were recorded [DOI] 10.1016/j.amsu.2020.10.061 PMC 바로가기 [Article Type] Case Series
Impact of tocilizumab administration on mortality in severe COVID-19Article Published on 2020-11-052022-10-04 Journal: Scientific Reports [Category] 신약개발, 임상, 치료법, [키워드] 95% confidence interval age Analysis benefit biologics chronic pulmonary disease clinical trial cohort study Comorbidity contribute Control COVID-19 COVID-19 patients Cytokine storm dataset death Dementia Diabetes Mellitus died discharged disease Evidence exclusion criteria expired healthcare providers heart failure hospital immune response Impact in-hospital mortality Inclusion individuals with COVID-19 Inflammatory response male malignancy management Medical research Mortality Myocardial infarction novel coronavirus disease Odds ratio Patient patients with COVID-19 Primary outcome provide severe COVID-19 severity significantly more single-center stratified Support the patient therapeutic thought Tocilizumab tocilizumab administration was performed worldwide pandemic [DOI] 10.1038/s41598-020-76187-y PMC 바로가기 [Article Type] Article
Pulmonary embolism in patients with COVID-19: characteristics and outcomes in the Cardio-COVID Italy multicenter studyOriginal Paper Published on 2020-11-032022-10-31 Journal: Clinical Research in Cardiology [Category] COVID-19, [키워드] d-dimer 95% CI Abstract Admission age Anticoagulant association baseline bleeding bleeding event BMI Cardiology Characteristics Chronic kidney disease Coagulopathy Cohort Concentration coronavirus disease COVID-19 COVID-19 patient critically ill patients cubic spline d -dimer death described discharge evaluated Evidence Follow-up hazard heart failure heterogeneous hospitalized COVID-19 patients implication In-hospital death in-hospital mortality incidence investigated Italy less linear males multicenter occur outcome Patient proportion Pulmonary embolism regression analysis Result subject supplementary material Support those without PE Thromboembolism Tocilizumab two subject unit variable Ventilated Ventilation [DOI] 10.1007/s00392-020-01766-y PMC 바로가기 [Article Type] Original Paper
The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic reviewVirology Published on 2020-11-022022-10-28 Journal: PeerJ [Category] COVID-19, [키워드] 95% CI absence Analysis antiviral therapy case-control study cause characterized clinical study clinical trials Combined COVID-19 COVID-19 mortality Critical cytokine drug dysregulated immune response Effect effective Efficacy Evaluating Evidence fatality group hypercytokinemia IL-6 IL-6 inhibitor include interleukin-6 lack lower mortality lymphocytopenia Mortality mortality rate Odds ratio pathophysiological performed positive pro-inflammatory cytokine producing quantitative synthesis random effect Randomized randomized control trial reducing Research Result SARS-CoV-2 severe COVID-19 Standard of care suppress systematic analysis systematic review TCZ the disease Tocilizumab treat Treatment Trial [DOI] 10.7717/peerj.10322 PMC 바로가기 [Article Type] Virology
Interleukin-6 in Covid-19: A systematic review and meta-analysis코로나19의 인터루킨-6: 체계적인 검토 및 메타 분석Meta-Analysis Published on 2020-11-012022-09-11 Journal: Reviews in Medical Virology [Category] SARS, 바이오마커, [키워드] 95% confidence interval 95%CI activate authors clinical outcomes Concentration COVID-19 cytokine Cytokine storm demonstrated disease dysregulated elevated eligible Evidence exploratory study for inclusion Grey literature host immune responses host response ICU admission IL-6 IL-6 level IL-6 levels IL6 immune responses Immunological response inhibition interleukin interleukin-6 Intervention management Meta-analysis moderate Patient random effect required Risk of bias SARS-CoV-2 searched Sensitivity analyses sensitivity analysis significantly suggested systematic review Therapeutics Tocilizumab were assessed [DOI] 10.1002/rmv.2141 PMC 바로가기 [Article Type] Meta-Analysis
Kidney transplant patients with SARS-CoV-2 infection: The Brescia Renal COVID task force experienceSARS-CoV-2 감염 신장 이식 환자: Brescia Renal COVID 태스크포스 경험Multicenter Study Published on 2020-11-012022-09-11 Journal: American journal of transplantation : official jou [Category] SARS, 치료제, [키워드] Acute kidney injury acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome acute respiratory syndrome coronavirus addition Admission age antiviral drugs ARDS average Azithromycin baseline Brescia C-reactive protein Clinical characteristics clinical research/practice Cohort coronavirus coronavirus disease Coronavirus disease 2019 COVID COVID-19 D-dimer death Dexamethasone died disease Dyspnea higher risk Hydroxychloroquine Immunosuppression increased risk Infection infection and infectious agents - viral infectious infectious agent infectious agents Infectious disease kidney Kidney disease kidney disease: infectious. kidney transplant lack lymphopenia Methylprednisolone Mild Mild disease Older outcome Outpatient outpatients Patient patients patients with SARS-CoV-2 reduction renal required respiratory respiratory distress Respiratory distress syndrome risk risk factor Risk factors risk of death SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 severe symptoms syndrome tacrolimus the patient thrombocytopenia Tocilizumab Withdrawal [DOI] 10.1111/ajt.16176 PMC 바로가기 [Article Type] Multicenter Study
Use of the interleukin 6 inhibitor tocilizumab in Japanese patients with cytokine release syndrome caused by COVID-19-related acute respiratory distress syndrome: A case series일본 코로나19 관련 급성호흡곤란증후군에 의한 사이토카인 분비 증후군 환자에서 인터루킨 6 억제제 토실리주맙의 사용 증례 시리즈Article Published on 2020-11-012022-09-12 Journal: Respiratory investigation [Category] 진단, [키워드] acute respiratory distress case sery caused Cytokine release syndrome inhibitor Japanese Patient Tocilizumab [DOI] 10.1016/j.resinv.2020.09.006 PMC 바로가기 [Article Type] Article